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Abstract
Background: COPD prevalence is highly variable and geographical altitude has been linked to it, yet with conflicting
results. We aimed to investigate this association, considering well known risk factors.
Methods: A pooled analysis of individual data from the PREPOCOL-PLATINO-BOLD-EPI-SCAN studies was used to
disentangle the population effect of geographical altitude on COPD prevalence. Post-bronchodilator FEV1/FVC
below the lower limit of normal defined airflow limitation consistent with COPD. High altitude was defined as
>1500 m above sea level. Undiagnosed COPD was considered when participants had airflow limitation but did
not report a prior diagnosis of COPD.
Results: Among 30,874 participants aged 56.1 ± 11.3 years from 44 sites worldwide, 55.8% were women, 49.6%
never-smokers, and 12.9% (3978 subjects) were residing above 1500 m. COPD prevalence was significantly lower
in participants living at high altitude with a prevalence of 8.5% compared to 9.9%, respectively (p < 0.005). However,
known risk factors were significantly less frequent at high altitude. Hence, in the adjusted multivariate analysis, altitude
itself had no significant influence on COPD prevalence. Living at high altitude, however, was associated with
a significantly increased risk of undiagnosed COPD. Furthermore, subjects with airflow limitation living at high
altitude reported significantly less respiratory symptoms compared to subjects residing at lower altitude.
Conclusion: Living at high altitude is not associated with a difference in COPD prevalence after accounting
for individual risk factors. However, high altitude itself was associated with an increased risk of undiagnosed COPD.
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Background
COPD is a common condition worldwide, but prevalence
estimates are highly variable by time, geography, or other
factors beyond age and smoking, which can only partly ex-
plain its population variability. Geographical altitude has
been linked previously to COPD prevalence, yet with con-
flicting results [1–9]. First, the PLATINO study found that
the greater the altitude, the lower the prevalence of COPD
in five Latin American capitals [1]. In contrast, the PRE-
POCOL study, conducted in five Colombian cities, re-
ported increasing COPD prevalence with higher altitude
[2]. The influence of altitude on other medical conditions
has been previously reported. For instance, reports con-
sistently conclude that pulmonary hypertension and right
heart failure have a higher prevalence in specific areas at
high altitudes [10, 11]. On the other hand results from the
Swiss National Cohort Study indicate that there is lower
mortality from coronary heart disease and stroke at higher
altitude [12, 13]. Tuberculosis incidence and mortality
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decreases with altitude, whereas mortality for pneumonia
and influenza increases with altitude [14, 15].
Potential mechanisms behind the assumed impact of
altitude on COPD prevalence are highly speculative
including that altitude could induce a higher growth of
airways relative to lung size, leading to an increased
FEV1/FVC ratio. This may be an adaptation to external
circumstances at high altitude such as chronic hypoxia,
the necessary increase in resting ventilation or extreme
physical performance, like in Sherpa populations [4, 16].
The PREPOCOL-PLATINO-BOLD-EPI-SCAN preva-
lence and underdiagnosis study was recently published
[17]. This study pooled representative samples of adults
aged 40 years and older randomly selected from well-
defined administrative areas worldwide (44 sites from 27
countries), and has the potential to help to disentangle
the population effect of geographical altitude on COPD
prevalence. The primary objective of this analysis was to
determine the association of COPD prevalence with alti-
tude, taking into account well known COPD risk factors.
Secondary objectives were to determine the association
of COPD underdiagnosis with altitude and to determine
the association of reported symptoms in participants
with airflow limitation with altitude.
Some of the results of this study have been previously
reported as an abstract [18].
Methods
Study populations
The PREPOCOL-PLATINO-BOLD-EPI-SCAN study
methods have been described in detail elsewhere [17]. In
summary, we used data from 30,874 participants enrolled
in the following epidemiologic surveys: (1) BOLD, (2) PLA-
TINO, (3) EPI-SCAN, and (4) PREPOCOL [1, 2, 19, 20].
The BOLD study [19, 21] is an ongoing population-
based survey on COPD epidemiology. Field work for the
data included was done from 2003 to 2012 and includes
data from 16,218 men and women aged ≥40 years in 23
sites. Complete information, including questionnaire data
and post-bronchodilator (post-BD) spirometry, were re-
corded. Details of the study protocol and prevalence of
airway obstruction have been reported elsewhere [19, 21].
PLATINO was launched in 2002 in five Latin American
cities in five countries. Complete information, including
questionnaire data and post-BD spirometry, were re-
corded for 5315 participants aged ≥40 years [1, 22].
EPI-SCAN was a population-based survey conducted
in 11 areas of Spain in 2007. Complete information, in-
cluding questionnaire data and post-BD spirometry,
were recorded for 3802 subjects aged ≥40 years [20, 23].
PREPOCOL was an urban population-based study con-
ducted in five Colombian cities in 2003 to 2004. Question-
naire data and post-BD spirometry were recorded for
5539 subjects aged ≥40 years [2].
For all surveys, exclusion criteria were mental illness,
institutionalization, inability to conduct spirometry, and
contraindications to spirometry or salbutamol.
Study measures
Post-BD spirometry after two puffs (200 μg) of salbuta-
mol was performed in the four included studies. In both
BOLD and PLATINO studies, spirometry was done
according to American Thoracic Society (ATS) criteria
[24] by trained and certified technicians using the ndd
EasyOne spirometer (ndd Medical Technologies, Andover,
MA, USA and Zurich, Switzerland). EPI-SCAN followed
the same guidelines but used the MasterScope CT spirom-
eter (VIASYS Health Care, Hoechberg, Germany). In
PREPOCOL, spirometry was performed according to ATS
criteria using the MicroLoop spirometer (Micro Medical
Ltd., Rochester, Kent, UK). Quality control measures were
done according to each study protocol [1, 2, 19–23]. In
summary, all interviews and examinations were performed
by certified staff, the spirometers were calibrated regularly
and the spirometry results were reviewed centrally for
quality by a third person. Moreover, regular feedback
about the quality of their performance was given to each
field worker during the period of data collection and
retraining was undertaken as necessary.
Questionnaire
The questionnaires used for the BOLD study [21], EPI-
SCAN [23], PLATINO [22], and PREPOCOL [2] were ad-
ministered by trained and certified staff in the participants’
native language and included information on respiratory
symptoms, respiratory diagnoses, and risk factors for
COPD. The questionnaires were translated from English
into the study site language and then translated back to
ensure accuracy.
Definitions
COPD was defined by post-BD FEV1/FVC below the
lower limit of normal (LLN) (persistent airflow limitation)
and the Third National Health and Nutrition Examination
Survey (NHANES) reference equations [25] were used to
calculate predicted values. Ever smoking (current or
former smoking) was defined as smoking >20 packs of cig-
arettes in a lifetime or more than one cigarette a day for
1 year. A prior lung function test was defined as present
when the question, “Has a doctor or other health-care
provider ever had you blow into a machine or device to
measure your lungs?” was answered affirmatively. In case
of doubt, the interviewers were able to explain the differ-
ence between a peak flow meter and a spirometer. A self-
reported diagnosis of COPD, emphysema, or chronic
bronchitis was based on questionnaire response (“Has a
doctor or health-care provider ever told you that you
have/had…?”). The reported diagnosis of COPD was
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considered correct if it was accompanied by post-BD air-
flow limitation (FEV1/FVC<LLN) at the time of the study
visit. Undiagnosed COPD was considered when partici-
pants had post-BD FEV1/FVC<LLN but were not given a
diagnosis of COPD by a physician or health-care profes-
sional. Severity of self-reported dyspnoea was recorded
according to the modified Medical Research Council dys-
pnoea scale (0–4), with dyspnoea defined as present with
a score ≥ 1. Presence of self-reported cough, phlegm, and
wheezing was assessed using the following or similar
questions: “Do you usually cough when you don’t have a
cold?”; “Do you usually bring up phlegm from your chest,
or do you usually have phlegm in your chest that is diffi-
cult to bring up when you don’t have a cold?”; “Have you
ever had wheezing or whistling in your chest in the last 12
months?”.
Occupational exposure to dust or fumes was assessed by
questionnaire. Additional measures evaluated included
body mass index (kg/m2), total number of years of educa-
tion, and self-reported physician-diagnosed comorbidities
like tuberculosis or heart disease.
High altitude was defined as a geographical altitude of
more than 1500 m above sea level. Although there is no
generally acknowledged definition, in literature it is widely
accepted as being the cut-off to influence the human body
physiology [26–29].
The altitudes of all cities/sites were obtained from the
original publications and, if not published, from eleva-
tionmap.net (http://www.elevationmap.net) in June 2016.
Statistical analysis
Data quality was centrally controlled, and a standardized
template to translate all coding was applied. Variables
were then double-checked by each principal investigator,
and data considered as potential errors or outliers were
individually discussed, and either confirmed or removed.
Comprehensive tabulations with ranges, means, and SDs
of all quantitative variables, and percentages of all qualita-
tive variables were available for each study. All statistics
were performed using R-3.3.0 (https://www.r-project.org).
Results are expressed as mean ± SD for quantitative
variables and count (percentage) for discrete variables.
Parametric t-test, nonparametric Mann-Whitney U test,
chi-square tests, and Spearman rank correlation coef-
ficient were used to investigate differences, wherever
appropriate. A Weibull model with logarithmic values for
altitude was used for the scatterplot in Figs. 1 and 2.
A multivariate logistic regression model was used to
examine the association of altitude with COPD preva-
lence while adjusting for sex, age, body mass index, level
of education, smoking status, former tuberculosis, and a
history of occupational exposure to dust.
Furthermore, a subgroup analysis in all participants
with FEV1/FVC<LLN was performed to evaluate differ-
ences in reported symptoms at different altitudes.
In all analyses p < 0.05 was considered statistically
significant.
Results
Among 30,874 participants aged 56.1 ± 11.3 years from 44
sites worldwide, 55.8% were women, and 49.6% never-,
27.5% former- and 22.9% current-smokers. Overall, 12.9%
or 3978 persons were residing at elevations above 1500 m,
while the majority (51.3%) of the participants was living at
altitudes less than 250 m above sea level. More de-
tailed information on demographics, smoking status,
geographical altitude and COPD prevalence by site is
presented in Tables 1 and 2.
As shown in Table 3, COPD prevalence was significantly
lower in participants living at high altitude defined as
>1500 m above sea level, with a prevalence of 8.5% com-
pared to 9.9%, respectively (p < 0.005). As seen in Fig. 1
Fig. 1 Scatterplot of the association of COPD prevalence by site (%) with altitude (m), with regression line explored by sex
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this result was consistent for both men and women with
Spearman’s rank correlation coefficients of −0.162
(p = 0.294) and −0.254 (p = 0.096), respectively. However,
risk factors for airflow limitation such as smoking, a history
of dusty work environment, or former tuberculosis were
significantly less frequent at high altitude. Participants from
high altitude were on average significantly younger and
reported fewer years of education, see Table 3.
The results of the multivariate analysis adjusted for sex,
age, body mass index, level of education, smoking status,
and a history of occupational exposure to dust, as plotted
in Table 4, do not show any significant association
between living at high altitude (defined as >1500 m above
sea level) and COPD prevalence.
Interestingly, people with airflow limitation (FEV1/
FVC<LLN) living at high altitude are at significantly
increased risk of not receiving a diagnosis of COPD
(85.8%) compared to subjects at altitudes <1500 m (80.8%).
This association was seen in both sexes with Spearman’s
rank correlation coefficients of 0.084 (p = 0.586) for males
and 0.189 (p = 0.219) for females (Fig. 2).
Only 4.1% of high altitude residents reported a previous
lung function test, and only 3.9% stated a previous diagno-
sis of COPD compared to 28.1% and 5.1% of subjects
living at altitudes <1500 m, respectively (Table 3). These
differences were statistically significant. No significant
difference was seen in the proportion of correct prior
diagnosis of COPD.
Figure 3 illustrates that participants living at high alti-
tude, though having airflow limitation (FEV1/FVC<LLN),
reported significantly less respiratory symptoms like cough,
phlegm, dyspnoea or wheeze, compared to subjects resid-
ing at lower altitudes.
Discussion
Our results indicate that living at high altitude is associ-
ated with a lower COPD prevalence. However, this could
be considered an example of ecological fallacy, and in the
multivariate analysis taking into account individual con-
founders, the association of altitude with COPD preva-
lence disappeared. Furthermore, living at high altitude was
linked to an increased risk of undiagnosed COPD.
In the past, geographical altitude has been linked to
COPD prevalence. Until now, the results concerning this
topic were inconsistent. In some articles, an association
between high altitude and higher COPD prevalence was
mentioned, whereas other authors stated a possible
protective effect of altitude for COPD.
Fig. 2 Scatterplot of the association of COPD underdiagnosis by site (%) with altitude (m) with regression line explored by sex
Table 1 Characteristics of participants
Characteristics Total n = 30,874
Sex, n (%) Female 17,230 (55.8)
Male 13,644 (44.2)
Smoking status, n (%) Never-smoker 15,308 (49.6)
Former smoker 8479 (27.5)
Current smoker 7065 (22.9)
Missing information 22 (0.07)
Age in years, mean (± SD) 56.1 (±11.3)
Age in decades, n (%) 40–49 10,828 (35.1)
50–59 9038 (29.3)
60–69 6466 (20.9)
70–79 3691 (12.0)
≥80 851 (2.8)
Geographical altitude in meters, mean (± SD) 521.8 (±687.8)
Geographical altitude, n (%) 0–250 15,823 (51.3)
250–500 3437 (11.1)
500–750 2737 (8.9)
750–1500 4899 (15.9)
>1500 3978 (12.9)
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Table 2 Altitude and prevalence of COPD (post-BD FEV1/FVC<LLN) by site and ascending order of altitude
Site Study Altitude (m) COPD prevalence (%)
1 Bergen, Norway BOLD 5 12.5
2 Mumbai, India BOLD 5 6.8
3 Barcelona, Spain EPI-SCAN 10 10.7
4 Vigo, Spain EPI-SCAN 10 4.8
5 Manila, Philippines BOLD 11 8.5
6 CapeTown, South Africa BOLD 14 19.0
7 Guangzhou, China BOLD 18 7.8
8 Baranquilla, Colombia Prepocol 18 3.6
9 Sydney, Australia BOLD 19 10.9
10 Nampicuan, Philippines BOLD 20 14.3
11 Uppsala, Sweden BOLD 21 9.3
12 London, England BOLD 22 16.0
13 Sevilla, Spain EPI-SCAN 23 4.9
14 Adana, Turkey BOLD 28 14.3
15 Vancouver, Canada BOLD 32 12.3
16 Montevideo, Uruguay Platino 35 11.9
17 Sousse, Tunisia BOLD 38 5.0
18 Tartu, Estonia BOLD 39 7.0
19 Maastricht, Netherlands BOLD 53 18.2
20 Reykjavik, Iceland BOLD 54 11.0
21 Lisbon, Portugal BOLD 56 11.5
22 Hannover, Germany BOLD 59 8.9
23 Cordoba, Spain EPI-SCAN 133 9.4
24 Krakow, Poland BOLD 214 13.7
25 Oviedo, Spain EPI-SCAN 239 11.0
26 Ife, Nigeria BOLD 266 6.9
27 Lexington, USA BOLD 291 15.2
28 Salzburg, Austria BOLD 424 15.8
29 Huesca, Spain EPI-SCAN 457 7.2
30 Vic, Spain EPI-SCAN 497 5.7
31 Santiago, Chile Platino 543 9.7
32 Pune, India BOLD 560 6.1
33 Requena (Valencia), Spain EPI-SCAN 588 6.2
34 Madrid La Princesa, Spain EPI-SCAN 648 10.9
35 Madrid La Paz, Spain EPI-SCAN 648 6.6
36 Sao Paulo, Brazil Platino 800 11.1
37 Burgos, Spain EPI-SCAN 864 3.9
38 Caracas, Venezuela Platino 950 8.5
39 Bucaramanga, Colombia Prepocol 960 5.3
40 Cali, Colombia Prepocol 995 5.6
41 Medellin, Colombia Prepocol 1538 10.6
42 Srinagar, India BOLD 1587 16.4
43 Mexico City, Mexico Platino 2240 3.8
44 Bogotá, Colombia Prepocol 2640 5.2
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PLATINO explored the association between altitude
and COPD prevalence and reported that the prevalence
was lowest in Mexico City (2240 m above sea level) and
highest in Montevideo (35 m above sea level). There was
a perfect correlation between the ranks of altitude in the
five cities and the COPD prevalence rates (Spearman
rank correlation coefficient − 1.0) [1]. It was noted that
this finding was consistent with similar reports from the
Himalayas [4, 16].
The PREPOCOL study reported opposite results [3]. In
the general population without airflow limitation both
FVC and FEV1 were significantly higher at higher altitude.
However, FEV1 proportionally increased a little more than
FVC, which could increase the FEV1/FVC ratio and de-
crease its ability to define the population with airflow limi-
tation at a higher altitude. A non-significant tendency
toward higher COPD prevalence with higher altitude was
found, ranging from 6.2% in Barranquilla (18 m above sea
level) to 13.5% in Medellín (1538 m above sea level) [2].
A recent study conducted in four Peruvian regions re-
ported that COPD prevalence was highest at the highest
altitude, with a RR = 1.6 versus sea level [5], therefore
being more consistent with PREPOCOL.
Laniado et al. [6] reported a COPD case-finding study
that included 27 Mexican cities, within an altitude range
from 1 to 2680 m above sea level. They described a weak
Table 3 Demographic characteristics and risk factors for COPD in subjects living at low (<1500 m) and high (>1500 m) altitude
Characteristics Altitude <1500 m Altitude >1500 m p-value
n = 26,896 n = 3978
COPD prevalence (%) 9.9 8.5 <0.005
Mean FEV1 (Litre, SD) 2.66 (0,85) 2.45 (0.78) 0.010
Mean FVC (Litre, SD) 3.47 (1.05) 3.20 (0.90) <0.001
Mean FEV1/FVC (SD) 76.8 (8.8) 76.2 (10.0) <0.001
Sex – female (%) 54.9 62.1 <0.001
Age (Mean, SD) 56.2 (11.3) 55.1 (11.3) <0.001
Never-smoker (%) 48.6 56.5 <0.001
Dusty job (%) 36.1 24.5 <0.001
Tuberculosis (%)a 3.5 0.4 <0.001
Education >12 years (%) 23.6 9.5 <0.001
Prior lung function test, ever (%)b 28.1 4.1 <0.001
Self-reported diagnosis of COPD (%) 5.1 3.9 <0.001
Proportion of correct prior diagnosis of COPD (%) 37.0 31.2 0.158
Proportion of undiagnosed COPD (%) 80.8 85.8 0.029
a14, 691 missing values
b5, 598 missing values
Table 4 Crude and adjusted odds ratios for COPD (FEV1/FVC<LLN)
Variable OR (crude) (95% CI) p-value OR (multivariate model) (95% CI) p-value
Altitude <1500 1 1
>1500 0.85 (0.75; 0.95) 0.005 0.90 (0.80; 1.02) 0.111
Sex Male 1 1
Female 0.73 (0.68; 0.79) <0.001 0.94 (0.86; 1.02) 0.119
Age in years 1.04 (1.04; 1.04) <0.001 1.05 (1.04; 1.05) <0.001
Years of education >12 1 1
9–12 1.24 (1.11; 1.39) <0.001 1.16 (1.03; 1.30) 0.015
<9 1.48 (1.33; 1.64) <0.001 1.24 (1.12; 1.39) <0.001
Smoking status Never 1 1
Former 1.97 (1.79; 2.16) <0.001 1.78 (1.61; 1.97) <0.001
Current 2.78 (2.53; 3.05) <0.001 3.40 (3.08; 3.76) <0.001
Dusty job 1.37 (1.27; 1.48) <0.001 1.18 (1.09; 1.29) <0.001
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(−0.31; p < 0.0001) although significant negative correl-
ation between altitude and COPD prevalence. The COPD
rate for cities located ≤1000 m was 32.7% vs 16.4% for cit-
ies located >1000 m (p < 0.0001); the rate for cities located
at ≤2000 m was 22.7% vs 15.6% for those >2000 m.
A recent study by Chan et al. analysed the geographic
disparity in mortality rates in Taiwan and found a statis-
tically significant inverse relationship between COPD
mortality and altitude [7].
A recent meta-analysis by Aaron et al. of 80 articles
published during 2003–2014 found a protective effect of
high elevation above sea level for COPD [9]. However,
risk factors were only analysed on country-level and not
on an individual subject level.
Our study has a number of strengths that help to disen-
tangle these conflicting results. To our knowledge, it is the
largest analysis (n > 30,000) of the effect of altitude on
COPD prevalence with a multinational approach, includ-
ing various ethnicities and races. Both spirometry and
bronchodilator testing were conducted with similar proto-
cols, which likely reduces bias due to methodologic issues.
By using the LLN, we avoided problems associated with
the use of the fixed ratio of FEV1/FVC, allowing us to bet-
ter compare results across studies [30].
A high prevalence of spirometric restriction is likely to
occur in low-income countries, and low FVC is likely re-
lated to poverty, low birth weight, poor diet, early infec-
tions, and exposure to indoor air pollution (burning of
biomass fuel) [31–36]. Because local prediction equations
may underestimate the local severity, and to be consistent
with earlier BOLD publications we deliberately used the
LLN for height, age, and sex on the basis of the Third Na-
tional Health and Nutrition Examination Survey reference
population [25].
COPD mortality is associated with low vital capacity
[37]. As the prognostic significance of a given FVC is in-
dependent of ethnicity [38], we decided not to adjust the
LLN for ethnicity.
High rates of undiagnosed COPD at high altitude may
be influenced by the fact that these subjects tend to re-
port significantly less respiratory symptoms. This result
is consistent with a previous analysis of our group where
COPD underdiagnosis was associated with a lack of re-
ported respiratory symptoms, no previous spirometry
and lower education amongst others [17]. However, to
reduce underdiagnosis is relevant for COPD patients
considering that Çolak et al. reported recently that indi-
viduals with undiagnosed symptomatic COPD have an
increased risk of exacerbations, pneumonia, and death.
Additionally, even individuals with asymptomatic un-
diagnosed COPD had an increased risk of exacerbations
and pneumonia [39, 40].
Furthermore, there is only a poor correlation between
reported COPD symptoms and lung function (FEV1),
and reported symptoms vary in different studies [41].
Hence, other circumstances that come with living at
high altitude such as greater poverty, poorer education,
lower health literacy, and lack of access to health care
resources, may play a role in underdiagnosis of COPD.
Although the proportion of subjects with a previous
lung function test is far higher at low altitude, this did not
influence the proportion of correct diagnoses of COPD.
Fig. 3 Self-reported respiratory symptoms by altitude in subjects with COPD (FEV1/FVC<LLN)
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However, some limitations must be noted. All four
surveys used different tools and brands of spirometers
with somewhat different protocols and quality control.
Nevertheless, all spirometers were calibrated and set up to
the same ATS/European Respiratory Society guidelines.
International variation was also seen across the 23 BOLD
sites using the same spirometer (ndd EasyOne), standard-
ized protocol and quality control. Countries assessed are
in different stages of the tobacco epidemic, perhaps even
by region and other risk factors have a variable distribu-
tion, for instance biomass fuel, occupational exposure,
educational and poverty levels. However, the PLATINO
study has shown that underdiagnosis is as common in
subjects with airflow limitation who never smoked as in
ever-smokers [42].
Although we adjusted for education as an indicator of
socioeconomic status in our multivariate model, there
may be other factors that influence COPD prevalence
that we were not able to assess. For example, it has been
shown, that Hispanic ethnicity is inversely associated
with spirometric COPD prevalence even after adjust-
ment for smoking [43]. Occupational exposure to dust
was assessed using different questionnaires for work-
place exposures in the original studies. Hence, a recall
bias may be possible concerning this risk factor.
Some additional determinants of COPD prevalence for
example indoor and outdoor air pollution, and biomass
exposure [44–46] were not assessed in all the included
studies and therefore not analysed. Hence, further re-
search is needed regarding these parameters. Addition-
ally, as a decreasing trend in COPD prevalence in very
high altitude cities (> 2000 m above sea level) was seen,
further research in the field of COPD prevalence at very
high altitude is desirable.
Although the proportion of missing information con-
cerning most parameters was negligible, there was no
data available about former tuberculosis in 14,691 sub-
jects and in 5598 individuals about a prior lung func-
tion test. Altitude of all study sites was taken from only
one geographic point, the central agglomeration where
the study centre was located. These study sites had
different catchment areas wherein the altitude of the
actual residence of the subjects may vary. However, as
the main results of our analysis are based on differences
between low and high altitude (>1500 m above sea
level), minor differences in altitude should not influence
the results. The effect of birth place, seasonal traveling
and other individual movements, should produce non-dif-
ferential effects. Unfortunately, we do not have any
information if study subjects lived on the same alti-
tude during their whole life or have moved up or
down. This may affect disease prevalence as described
by Faeh et al. [12] in their Swiss study for coronary
heart disease and stroke.
Conclusions
Living at high altitude is associated with a lower COPD
prevalence, but it seems that other related individual risk
factors are accountable for this finding. After adjustment
for confounders there is no association between high alti-
tude and COPD prevalence. However, high altitude itself
is associated with an increased risk of undiagnosed COPD.
This may be caused by the fact that individuals at high
altitude were less symptomatic despite having an obstruct-
ive pattern in their lung function test. Further research is
needed to evaluate other risk factors like biomass expos-
ure, indoor and outdoor air pollution, and poverty.
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